Background. The optimal reduction of immunosuppressive therapy (IST) in renal transplant patients with post-transplant lymphoproliferative disorders (PTLDs) is uncertain. As chemotherapy is immunosuppressive, IST may be stopped during this time without compromising graft function. Subsequent longterm reduction of IST reduces relapse risk, but may increase risk of graft rejection. Methods. We performed a retrospective, matched cohort study of adult renal transplant patients in whom IST was ceased during chemotherapy and resumed at lower dose (calcineurin inhibitor at 50%, prednisolone ≤10 mg daily, no third agent) approximately 6 weeks after chemotherapy. Outcomes were compared with those of renal transplant patients without PTLD, matched for creatinine at equivalent time post-transplant that PTLD was diagnosed in cases, as well as for age, gender and year of transplant. Results. Twenty-four cases of PTLD occurring at a median of 9.2 years post-transplant were compared with 83 matched controls. PTLD cases were followed for a median of 11.9 years. Using competing risks analysis, time to 25% increase in serum creatinine was not significantly different between the two groups [adjusted hazard ratio (HR) 1.8, 95% confidence interval (CI) 0.89-3.6]. Similar results were obtained using multivariable Cox regression analysis (HR 1.19, 95% CI 0.44-3.23).
frequent impairment of graft function [1, 3] . In many cases, the pathogenesis of PTLDs is related to Epstein-Barr virus (EBV)-mediated B cell proliferation in the setting of chronic immunosuppression and reduced T cell immune surveillance [5] [6] [7] [8] . EBV-related PTLD tends to occur in the early period posttransplant due to intensive immunosuppression, whereas EBVnegative disease is more common late after transplantation [2, 7] . An exception is primary central nervous system (CNS)-related PTLD, which commonly occurs late and is almost universally EBV-positive [9] .
Numerous therapies have been proposed to treat PTLDs, including immunosuppressive therapy (IST) reduction, antiviral therapy, combination chemotherapy, radiation therapy and more recently targeted antibody therapy such as rituximab as well as allogeneic EBV-specific cytotoxic T lymphocytes [10] [11] [12] [13] [14] [15] [16] . An increasing body of evidence suggests that IST reduction, rituximab and combination chemotherapy are the most effective modalities for long-term survival [11, 13, 17, 18] . More recent studies have recommended a sequential treatment approach with reduction in IST initially, followed by rituximab and then later CHOP chemotherapy in the event of residual or progressive disease [19] . Despite this, there is no definitive consensus on optimal management in PTLDs.
The optimal initial reduction in IST remains uncertain. Current guidelines recommend a 25-50% reduction in calcineurin inhibitor, continuation of steroids and cessation of other immunosuppression [11] . The European Best Practice guidelines for renal transplantation published in 2002 recommended a reduction in calcineurin inhibitor by at least 50% and stopping all other immunosuppressants apart from steroids [20] . This approach was supported by a study by Trappe et al. [21] , which examined 58 renal transplant recipients and found that patients treated with IST reduction plus chemotherapy and rituximab had non-inferior graft function at 1 year when compared with controls. However, the most recent update of the European guidelines does not include any recommendation on IST reduction [22] . As chemotherapy regimens used to treat PTLDs are inherently immunosuppressive, IST may even be stopped during this time without compromising graft function. Following initial therapy, long-term reduction of baseline IST is important to reduce the risk of PTLD relapse, but may increase the longterm risk of renal transplant rejection.
The aim of this study was to determine whether IST can be safely ceased during chemotherapy and re-instituted at a lower dose without having deleterious effects on renal graft function.
M AT E R I A L S A N D M E T H O D S
The study design was a retrospective matched cohort study of kidney transplant patients examining graft outcomes in PTLD cases compared with controls without PTLD. Forty-nine adult renal transplant patients were diagnosed with PTLD between 1994 and November 2010 at Princess Alexandra Hospital, Queensland, Australia. Data were gathered from retrospective chart review, as well as from lymphoma, renal and pathological databases. This retrospective study was approved by the Human Research and Ethics Committee of the Princess Alexandra Hospital.
Cases
On diagnosis of PTLD at our institution, initial management, in the absence of rejection, has been to reduce IST by halving the calcineurin inhibitor dose and ceasing the second agent (usually azathioprine or mycophenolate). In the event of a suboptimal response to IST reduction, chemotherapy or radiotherapy is commenced depending on histology and disease stage. Since 2004, single-agent rituximab has also been used with subsequent chemotherapy for those who did not achieve complete remission. About 25 patients diagnosed with PTLD were not included in this study cohort. Reasons for exclusion included early death before initiation of treatment (n = 4), insufficient data (n = 2), physician-initiated departure from the IST reduction protocol as the renal physician was not comfortable ceasing IST during treatment (n = 2) and concerns regarding acute or chronic rejection at the time of diagnosis of PTLD, thus limiting the ability to reduce IST (n = 5). Four of these latter patients had biopsy evidence of acute (n = 2) or chronic (n = 2) rejection, and one had a rising creatinine level after initial IST reduction. Ten patients were excluded because they did not receive CHOP-like chemotherapy. The management of these 10 patients included IST reduction only (n = 3), rituximab alone (n = 4), XRT alone (n = 1) and myeloma therapy or methotrexate-based therapy (n = 1 each). A further two patients were excluded as no matched control was identified.
Data were collected regarding time from transplant to diagnosis of PTLD, sex, age at time of transplant and diagnosis, histology of PTLD including Epstein-Barr virus encoded RNA status, monomorphic or polymorphic disease, early or late onset disease, staging, International Prognostic Index, performance status, elevated lactate dehydrogenase, PTLD treatment and outcome. Renal function (serum creatinine level) was assessed at the time of PTLD diagnosis, at the time of IST cessation, during chemotherapy, at 6 weeks, 3, 6 and 12 months, 2 years after chemotherapy and then annually until the time of last follow-up. The incidence of renal deterioration (defined as a persistent 25% increase in the serum creatinine level), need for dialysis and re-transplant were also assessed. Incidence of relapsed PTLD and overall survival (OS) were also evaluated. IST was recorded before, during and after chemotherapy.
Controls
The PTLD cases were compared with a matched cohort of 83 renal transplant patients without PTLD, which was obtained from the renal unit database. Controls were matched, blinded to outcome, for renal function at the equivalent time posttransplant that PTLD was diagnosed in the cases, as well as for age, gender and age at transplant. More detailed matching incorporating variables known to affect graft survival, such as year of transplant, diabetes and liver or deceased donor transplant, was unable to be performed due to the relatively small number of controls with equivalent good renal function to the cases. Incidences of renal function deterioration, need for dialysis and re-transplant and OS were assessed, as in the cases mentioned earlier.
Statistical analysis
The primary end point was time from study entry (date of PTLD diagnosis in cases or equivalent time post-transplant in controls) to significant renal function deterioration, defined as a ≥25% increase in serum creatinine concentration for ≥3 months or need for dialysis or re-transplantation. Secondary end points were time to renal allograft failure requiring dialysis or re-transplantation and OS. Time-to-event analyses were performed by Cox proportional hazards regression with clustered robust estimates of standard errors specified to take account of the intra-cluster correlations of each case-control cluster of patients. Death was treated as a competing risk for the two end points related to kidney failure. Additional competing risk survival analyses were therefore conducted for the kidney failure end points using the method of Fine and Gray [23] , with clustered robust estimates of standard errors. Multivariable competing risk analysis was conducted for time to 25% increase in the serum creatinine level by including the potentially confounding variables of diabetes, donor status and year of transplant. Multivariable analysis was not conducted for time to dialysis because there were too few events for a meaningful analysis. There was a strong suggestion that the effects of the potential confounding variables were different for cases and controls; hence, first-level interaction terms were included in the multivariable analysis. Statistically nonsignificant (P > 0.1) variables were dropped from the final multivariable model.
R E S U LT S

Patient characteristics
Twenty-four patients with PTLD were identified who had immunosuppression ceased during chemotherapy and subsequently resumed at a lower dose. Patient characteristics are summarized in Table 1 . At the time of PTLD diagnosis, 16 (67%) patients received dual combination IST (usually calcineurin inhibitor plus azathioprine or mycophenolate or prednisone), whereas 8 (33%) patients received triple combination IST (Table 1) .
All immunosuppression apart from steroids was ceased during chemotherapy. Twenty-two patients received anthracyclinebased chemotherapy. Two patients with primary CNS lymphoma were treated with non-anthracycline-containing primary CNS lymphoma-specific protocols [22] . Following chemotherapy, the calcineurin inhibitor was resumed at ≤50% of the original dose, whereas azathioprine or mycophenolate remained ceased. Prednisone was continued in 14 (58%) patients.
Matched controls
Eighty-three controls were identified, with a median of four matched controls per case (range one to four matches). The controls were well matched to the PTLD cases for age (at renal transplant), time from transplant, creatinine at an equivalent time post-transplant and gender (Table 2) . No other significant differences were identified, except that cases were transplanted significantly earlier than controls.
Renal function deterioration
During the period of follow-up, a ≥25% increase in serum creatinine concentration was observed in 11 of the 24 cases after a median period of 43.1 months, compared with 16 of the 83 controls after a median period of 31.4 months [Cox regression adjusted hazard ratio (HR) 2.2, 95% confidence interval (CI) 1.05-4.4, P = 0.04; method of Fine and Gray HR 1.8, 95% CI 0.89-3.6, P = 0.1] (Figure 1 ). There was no significant difference in the 5-year event rate for a ≥25% increase in creatinine between the cases (35%) and controls (20%) ( Table 3) . When multivariable analysis was performed to account for potentially confounding variables such as year of transplant, diabetes and donor status, there was no significant difference in 25% increase in creatinine between cases and controls (HR 1.19, 95% CI 0.44-3.23, P = 0.73) ( Table 4) .
End-stage renal failure
Three of the 24 cases experienced renal allograft failure and resumed haemodialysis at 1, 3.5 and 7 years post-diagnosis of PTLD and at 14, 19 and 21 years post-transplant, respectively. Three of the 83 controls required recommencement of dialysis at 79, 112 and 114 months post-transplant. There was no significant difference in the risk of needing dialysis between cases and controls, as assessed by the Cox regression analysis (HR 3.0, 95% CI 0.57-16.00, P = 0.19) and the method of Fine and Gray [23] (HR 2.5, 95% CI 0.47-13.00, P = 0.28) ( Table 3) .
Effect of rituximab on renal allograft outcomes
In the PTLD group, an additional subgroup analysis was conducted on the basis of whether or not the case received rituximab. Two (29%) of the seven cases treated with rituximab had a 25% increase in the serum creatinine level compared with 53% of those not receiving rituximab. However, the two that did have a 25% increase in the creatinine level went on to require dialysis compared with only one of the nine other cases that had a 25% increase in the creatinine level. The sample size was too small to conduct formal statistical analysis on these renal outcomes.
Treatment response
Fifteen patients received chemotherapy alone, whereas the remaining patients received chemotherapy in combination with rituximab (n = 7) and/or radiation therapy (n = 4). Twenty-one patients (87.5%) achieved complete remission whereas the remaining three had progressive disease and died early. Five patients who achieved complete remission relapsed. All these patients received some form of salvage therapy (chemotherapy, stem cell transplant or radiotherapy). Two of these patients achieved a sustained complete remission, whereas the remaining three died due to progressive disease or therapy-related complications. One patient who achieved a second complete remission later died from an unrelated cause.
Overall patient survival
At the time of analysis, 11 cases had died. Of these, seven died from PTLD or complications of therapy, and three died from seemingly unrelated causes and the cause of death for one patient was unknown after being lost to follow-up. In comparing OS between cases and controls by Cox regression analysis, there was clear evidence that the proportional hazards assumption was violated because a high proportion of deaths occurred early in the patients with PTLD lymphoma, compared with the controls (Figure 2) . A log-rank test (stratified by case-control cluster) showed evidence of a higher risk of death in the cases (5-year OS 70%) compared with the controls (5-year OS 94%) (P = 0.01).
D I S C U S S I O N
Chronic immunosuppression is implicated in the pathogenesis of PTLD, and reduction in IST is a key component in the management of these disorders. Currently, there is little evidence to inform the optimal reduction in IST in renal transplant patients diagnosed with PTLD.
In this study, we have demonstrated that IST can be safely ceased during chemotherapy for PTLD without causing an increased risk of renal allograft rejection in the short term. In fact, only one patient had a persistent deterioration in renal function within 6 months of IST cessation, and this occurred in the context of rapidly progressive lymphoma. A retrospective study by Trappe et al. [21] of 58 renal transplant patients with PTLD demonstrated that patients treated with reduction (rather than cessation) of IST, in combination with chemotherapy or rituximab, had non-inferior renal graft function at 1 year compared with controls. A possible explanation of this is that chemotherapy (with or without rituximab) induces prolonged immune suppression or immune tolerance to the allograft. In particular, CHOP-like regimens contain cyclophosphamide and highdose prednisolone, which are known potent immunosuppressants. Rituximab has also been successfully used to treat a variety of autoimmune disorders [24] [25] [26] , and thus these agents may well provide sufficient anti-rejection therapy to compensate for the cessation of the traditional IST such as calcineurin inhibitors and mycophenolate.
Our study also demonstrated that long-term IST reduction was not associated with any significant increase in the risk of chronic graft dysfunction. In the multivariate analysis, after taking into account confounding variables such as year of transplant, there was no significant difference in the risk of renal deterioration between cases and controls (HR 1.19, P = 0.73) when the calcineurin inhibitor was reintroduced at 50% baseline dose and prednisone was continued but without a third agent (azathioprine or mycophenolate). It is possible that PTLD itself may be a marker of patients who are more 'immunosuppressed' and hence identify a group less likely to develop renal allograft rejection, thus allowing for long-term IST reduction. This is also supported by data demonstrating that allograft rejection resulting in recommencement of dialysis is higher in the general renal transplant patients, compared with PTLD patients. At our institution, the 5-year rate of graft failure is 15.3%, which is higher than the rate for both cases and controls in our study, who were already at a median of 9 years posttransplant at study entry [27] . Certainly, prospective trials are needed to further address the long-term reduction in IST for these patients.
Myelosuppression and the consequent risk of infection are significant factors that must be considered when treating renal transplant patients with combination chemotherapy. In recent years, rituximab has been used as first-line therapy in conjunction with IST reduction to avoid the toxicity of combination chemotherapy [13] [14] [15] . There are little data on renal allograft outcomes when rituximab monotherapy and reduction in IST are used without chemotherapy. Our study included only patients receiving chemotherapy, and so our conclusions regarding safe cessation of IST cannot be extrapolated to this setting. It may be, however, that the immunosuppressive effect of rituximab alone is sufficient to protect renal allograft function when IST is reduced rather than ceased. Larger studies addressing this question are needed. Similarly, our data cannot be extrapolated to patients who have acute or chronic renal transplant rejection at the time of diagnosis of PTLD as such patients were excluded from our study.
There are several limitations to our study. It is a relatively small retrospective study with all the biases that such studies bring, such as recall, misclassification and selection bias, as well as the possibility of type 2 statistical error due to the small sample size. Also, the effect of PTLD itself on renal allograft function cannot be assessed when compared with non-PTLD controls, and direct comparison to other patients with PTLD who did not undergo cessation of immunosuppression was not possible due to the small numbers involved. Our cases were not able to be matched for all factors known to impact renal allograft survival. This may have biased our analysis of renal deterioration, although we used multivariate analysis to try and minimize this bias. Finally, two cases had to be excluded due to physician-initiated departure from the IST reduction protocol. Despite these limitations, we believe that the very long period of follow-up and case-control design add strength to our findings.
In summary, our study demonstrates that IST can be safely ceased during CHOP-like chemotherapy for PTLD in renal transplant patients. Furthermore, long-term reduction of IST post-chemotherapy does not appear to be associated with an increased risk of chronic graft dysfunction. Prospective trials are needed to address the optimal initial and long-term reduction of IST in PTLD.
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